Follow on our innovation
CIS Pharma at the Swiss RNA Therapeutics Summit in Bern
Bern, Switzerland, Thursday, January 26, 2023 - CIS Pharma attends the first Swiss RNA Therapeutics Summit in Bern. The Summit brings together stakeholders in the field of RNA Therapeutics from academia, biotechnology, pharma, manufacturing, [...]
Carrier and linker technology for targeted delivery of RNAi
Bubendorf, Switzerland, Tuesday, January 24, 2023 – CIS Pharma engages additional resources in 2023 to develop a novel linker/carrier system to conjugate ASO and siRNA for targeted delivery. To widen the therapeutic use of [...]
B7H3 nanobody program successfully progressing into next stage
Bubendorf, Switzerland, Wednesday, January 18, 2023 - CIS Pharma has identified its lead anti-B7H3 nanobody displaying promising affinity to the target. The production of the final candidate is up-scaled and the nanobody is labeled [...]
Anti-L1CAM radioligand efficacious against ovarian cancer in mouse Xenograft tumor model
Bubendorf, Switzerland, Tuesday, December 20, 2022 - CIS Pharma has successfully tested its anti-L1CAM radioligand against ovarian cancer in a Xenograft mouse model. The antibody-based radioligand comprises chelators conjugated to the antibody site-sepcifically. Labeled [...]